Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial
2025 · Nature Communications · 1 citations
https://doi.org/10.1038/s41467-025-66667-y
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
8
Papers
16
Citations
2
h-index
1
i10-index
Busem Binboga Kurt is an academic researcher from Harvard University. The author has contributed to research in topics: Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 2, co-authored 7 publications.
Click to start Chat